Real-world experience measuring pain over time on ORILISSA

Home
Patient experience
Real-world experience

Pain reduction in women taking ORILISSA was evaluated in the LOTUS Study2

Real-world data are observational in nature, may be prospectively or retrospectively collected, and are not based on controlled clinical studies. Results from these cohorts may differ from those observed in clinical practice and are not presented in the ORILISSA Prescribing Information. Pain levels were assessed using a 0-10 numeric rating scale (NRS).

150 mg QD 150 mg QD
200 mg BID 200 mg BID

ORILISSA 150 mg QD

Dysmenorrhea

Mean dysmenorrhea pain reduction in LOTUS Study from baseline to month 62

Mean dysmenorrhea score
Baseline Month 22% Reductionn=59 n=53 45% Reductionn=47 n=40 n=35 56% Reductionn=30
  • ORILISSA 150 mg QD

Non-menstrual pelvic pain (NMPP)

Mean NMPP pain reduction in LOTUS Study from baseline to month 62

Mean NMPP score
Baseline Month 18%Reductionn=44 n=41 37%Reductionn=37 n=33 n=30 44% Reductionn=28
  • ORILISSA 150 mg QD

Safety outcomes were not a primary objective of the LOTUS Study.

ORILISSA 200 mg BID

Dysmenorrhea

Mean dysmenorrhea pain reduction in LOTUS Study from baseline to month 62

Mean dysmenorrhea score
Baseline Month 32% Reductionn=28 n=25 71% Reductionn=21 n=19 n=14 81% Reductionn=13
  • ORILISSA 200 mg BID

Non-menstrual pelvic pain (NMPP)

Mean NMPP pain reduction in LOTUS Study from baseline to month 62

Mean NMPP score
Baseline Month 26% Reductionn=24 n=22 53%Reductionn=18 n=15 n=10 59% Reductionn=9
  • ORILISSA 200 mg BID

Dyspareunia

Mean dyspareunia pain reduction in LOTUS Study from baseline to month 62

Mean dyspareunia score
Baseline Month 31% Reductionn=22 n=20 47% Reductionn=17 n=14 n=10 39%Reductionn=9
  • ORILISSA 200 mg BID

Safety outcomes were not a primary objective of the LOTUS Study.

Pharmacology